Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Trial Profile

A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs MK-2118 (Primary) ; MK-2118 (Primary) ; Pembrolizumab (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Aug 2018 Planned number of patients changed from 110 to 135.
    • 24 Apr 2018 MK-2118 subcutaneous (SC) injection in combination with pembrolizumab IV infusion will also be studied, patient number changed from 66 to 110. Treatment arms added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top